Yoji Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoji Sato has a total of 304 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Yasuda
Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki Ward, Kawasaki City, Kanagawa, 210-9501, Japan
27 shared publications Takuya Kuroda
Division of Cell-Based Therapeutic Products, National Institute of Health Sciences , Kawasaki
17 shared publicationsShinji Kusakawa
Division of Cell-Based Therapeutic Products, National Institute of Health Sciences , Kanagawa , Japan
11 shared publicationsAkifumi Matsuyama
Center for Reverse TR, Osaka Habikino Medical Center, Osaka Prefectural Hospital Organization, Habikino, Japan
9 shared publicationsRumi Sawada
Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki Ward, Kawasaki City, Kanagawa, 210-9501, Japan
9 shared publicationsKen Kono
Natl Inst Hlth Sci, Div Cell Based Therapeut Prod, Kanagawa, Japan
8 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Elsevier in Cytotherapy
Establishment and multisite evaluation of a MOLT-4 cell-based IL-2-independent growth assay to detect transformed cells in T-cell products
- 3 November 2026
- Published by Elsevier in Cytotherapy
Open AccessEstablishment and multisite evaluation of a MOLT-4 cell-based IL-2-independent growth assay to detect transformed cells in T-cell products
- 25 September 2026
- Published by Elsevier in Biologicals
- Vol. 96
Globally harmonized specifications: Implementing a patient-centric, enhanced control strategy – a meeting report
- 25 September 2026
- Published by Elsevier in Biologicals
- Vol. 96
Globally harmonized specifications: Implementing a patient-centric, enhanced control strategy – a meeting report
- Open Access
- 29 July 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (12)
Multi-site validation and applicability assessment of a practical three-dimensional colony formation assay for detecting malignantly transformed cells
- 29 July 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (12)
Open AccessMulti-site validation and applicability assessment of a practical three-dimensional colony formation assay for detecting malignantly transformed cells
- 19 February 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3) , 102
High-Contrast X-Ray Computed Tomography for Quantifying Amorphous Content in Melt-Quenched Acetaminophen
X-ray computed tomography (XRCT) allows for non-destructive three-dimensional observation and volumetric quantification of samples. It also allows for stru
- 19 February 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3) , 102
High-Contrast X-Ray Computed Tomography for Quantifying Amorphous Content in Melt-Quenched Acetaminophen
X-ray computed tomography (XRCT) allows for non-destructive three-dimensional observation and volumetric quantification of samples. It also allows for stru
- 10 February 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (2) , 96
Analysis of the Correlation Between Membrane Permeability in RPMI 2650 Cells and Human Nasal Absorption
Nasal drug delivery offers several advantages, such as rapid onset and avoidance of hepatic first-pass metabolism, making it a promising option for deliver
- 10 February 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (2) , 96
Analysis of the Correlation Between Membrane Permeability in RPMI 2650 Cells and Human Nasal Absorption
Nasal drug delivery offers several advantages, such as rapid onset and avoidance of hepatic first-pass metabolism, making it a promising option for deliver
- Open Access
- 28 December 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 116
Paddle attachments to mitigate coning in USP apparatus II
- 28 December 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 116
Open AccessPaddle attachments to mitigate coning in USP apparatus II
- Open Access
- 19 December 2025
- Published by Elsevier in Regenerative Therapy
- Vol. 31, 101052
Development of a digital analysis system for a novel 3D culture-based colony formation to detect malignantly transformed cells in human cell-based therapeutic products
- 19 December 2025
- Published by Elsevier in Regenerative Therapy
- Vol. 31, 101052
Open AccessDevelopment of a digital analysis system for a novel 3D culture-based colony formation to detect malignantly transformed cells in human cell-based therapeutic products
- Open Access
- 28 November 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 115
Pharmaceutical excipients that alter intestinal drug Absorption: A systematic review of Excipient–Drug interactions
- 28 November 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 115
Open AccessPharmaceutical excipients that alter intestinal drug Absorption: A systematic review of Excipient–Drug interactions
- 25 October 2025
- Published by Springer Nature
- Vol. 1486, 341-347
Viral Safety
Viral safety is an extremely important issue for the clinical application of cell therapy products. The viral contamination of products can lead to serious adverse events in patients treated with them. Therefore, it is strongly recommended to evaluate the viral safety of products using the most advanced science and technology available at the time, based on scientific rationality. We are also obligated to respond to society’s strong interest in and social demand for public health preservation. Because various types of cell therapy products have been developed, some measures to ensure viral safety for each product are common, and others should be addressed on a case-by-case basis. This chapter outlines the basic approach for viral safety confirmation for cell therapy products and introduces our recent work on viral safety using the next-generation sequencer.
- 25 October 2025
- Published by Springer Nature
- Vol. 1486, 341-347
Viral Safety
Viral safety is an extremely important issue for the clinical application of cell therapy products. The viral contamination of products can lead to serious adverse events in patients treated with them. Therefore, it is strongly recommended to evaluate the viral safety of products using the most advanced science and technology available at the time, based on scientific rationality. We are also obligated to respond to society’s strong interest in and social demand for public health preservation. Because various types of cell therapy products have been developed, some measures to ensure viral safety for each product are common, and others should be addressed on a case-by-case basis. This chapter outlines the basic approach for viral safety confirmation for cell therapy products and introduces our recent work on viral safety using the next-generation sequencer.
- Open Access
- 13 September 2025
- Published by Elsevier in Biologicals
- Vol. 92, 101859
Report of the fourth conference on next-generation sequencing (NGS) for adventitious virus detection in biologics for humans and animals: Validation and implementation of NGS
- 13 September 2025
- Published by Elsevier in Biologicals
- Vol. 92, 101859
Open AccessReport of the fourth conference on next-generation sequencing (NGS) for adventitious virus detection in biologics for humans and animals: Validation and implementation of NGS